FDA approves BioCryst drug to treat HAE swelling disorder; stock jumps 14%
Shares in Triangle pharmaceutical firm BioCryst surged 14% Friday morning after the company disclosed FDA approval of its drug to treat a rare swelling disorder.
Copy and paste this URL into your WordPress site to embed
Copy and paste this code into your site to embed
